Universitäres Centrum für Tumorerkrankungen Mainz (UCT Mainz)
Klinisch orientierter Schwerpunkt / Johannes Gutenberg-Universität Mainz
Elger, T.; Battista, M.; Krajnak, S. et al.
WEEKLY PACLITAXEL IN REFRACTORY CHORIOCARCINOMAINTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Bd. 27. 2017 S. 1324-1324
Hainz, Tobias; Paul, Norbert W.
What Can We Do for You? The Role of Ethics Experts in Neuroscience.AJOB Neuroscience. Bd. 8. H. 1. 2017 S. 15-17
Ferreri, Andres J. M.; Cwynarski, Kate; Pulczynski, Elisa et al.
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trialLANCET HAEMATOLOGY. Bd. 4. H. 11. 2017 S. E510-E523
Elger, T.; Battista, M.; Macchiella, D. et al.
YOLK SAC TUMOR OF THE CLITORIS IN A FIFTEEN-MONTHS-OLD CHILDINTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. Bd. 27. 2017 S. 1325-1325
Lutz, Manfred P.; Zalcberg, John R.; Glynne-Jones, Rob et al.
2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer (vol 63, pg 11, 2016)EUROPEAN JOURNAL OF CANCER. Bd. 68. 2016 S. 208-209
Hahn, Susanne A.; Neuhoff, Annemarie; Landsberg, Jenny et al.
A key role of GARP in the immune suppressive tumor microenvironmentONCOTARGET. Bd. 7. H. 28. 2016 S. 42996-43009
Zhu, A. X.; Galle, P. R.; Kudo, M. et al.
A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)ANNALS OF ONCOLOGY. Bd. 27. 2016
Zhu, Andrew X.; Galle, Peter R.; Kudo, Masatoshi et al.
A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).JOURNAL OF CLINICAL ONCOLOGY. Bd. 34. H. 4. 2016
Kalder, M.; Mueller, T.; Fischer, D. et al.
A Review of Integrative Medicine in Gynaecological OncologyGEBURTSHILFE UND FRAUENHEILKUNDE. Bd. 76. H. 2. 2016 S. 150-155
Motzek, A; Knezevic, J; Switzeny, O et al.
Abnormal hypermethylation at imprinting control regions in patients with S-Adenosylhomocysteine hydrolase (AHCY) deficiencyPlos One. 2016 S. 1-15